hydroxychloroquine has been researched along with Giant Cell Arteritis in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Giant Cell Arteritis: A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Studies included were trials in which: (1) the participants were classified as having GCA by the 1990 ACR criteria or biopsy proven disease; (2) parallel-group randomised control of at least 16 weeks duration had been conducted with at least 20 participants; (3) the design included either alternative adjunct immunosuppressant regimens, alternative GCs dosing or routes of administration; and (4) outcome data was included on either relapse rates or rates of infection." | 6.50 | Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. ( Loke, YK; MacGregor, AJ; Watts, RA; Yates, M, 2014) |
| " Studies included were trials in which: (1) the participants were classified as having GCA by the 1990 ACR criteria or biopsy proven disease; (2) parallel-group randomised control of at least 16 weeks duration had been conducted with at least 20 participants; (3) the design included either alternative adjunct immunosuppressant regimens, alternative GCs dosing or routes of administration; and (4) outcome data was included on either relapse rates or rates of infection." | 2.50 | Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. ( Loke, YK; MacGregor, AJ; Watts, RA; Yates, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Worm, S | 1 |
| Giot, JB | 1 |
| Courtoy, C | 1 |
| Gillet, E | 1 |
| Amrane, S | 1 |
| Huynen, P | 1 |
| Van Esbroeck, M | 1 |
| Prudent, E | 1 |
| Lepidi, H | 1 |
| Million, M | 1 |
| Moutschen, M | 1 |
| Raoult, D | 1 |
| Yates, M | 1 |
| Loke, YK | 1 |
| Watts, RA | 1 |
| MacGregor, AJ | 1 |
1 review available for hydroxychloroquine and Giant Cell Arteritis
| Article | Year |
|---|---|
Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dap | 2014 |
1 other study available for hydroxychloroquine and Giant Cell Arteritis
| Article | Year |
|---|---|
A case of giant cell arteritis associated with culture-proven Coxiella burnetii aortitis.
Topics: Aged; Anti-Bacterial Agents; Aorta, Abdominal; Aortitis; Coxiella burnetii; Doxycycline; Fluorodeoxy | 2018 |